Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7484295 | 0.92 | NAMPT (0.43) | NAMPTCYP17A1RAB9AMAP4K1ATR | |
| SCHEMBL2107971 | 0.88 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL18522430 | 0.87 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL743727 | 0.86 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMAP4K1METAP1 | |
| SCHEMBL692100 | 0.83 | HPGD (0.49) | MAPTGSK3BATRSIRT3TDP1 | |
| SCHEMBL13748300 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL3229288 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1GSK3B | |
| SCHEMBL30759207 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL30114700 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR | |
| SCHEMBL28390904 | 0.83 | NAMPT (0.47) | NAMPTCYP17A1RAB9AMETAP1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2024049929-A2 | PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED | PANNEX THERAPEUTICS INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4034239-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401969-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| WO-2021058416-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
| US-6359136-B1 | AZAINDOLE COMPOUND | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6265416-B1 | ANTICOAGULANTS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| CN-1068325-C | phenyl oxazolidinone antibacterial agents | PHARMACIA & UPJOHN CO LLC (US) | 2001-07-11 | — | — | CN | disclosed |
| EP-0997465-A1 | Azaindole derivatives and their use as antithrombotic agents | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5681959-A | DEPROTONATION OF A 2-AMINO-3-ALKYLPYRIDINE WITH AN ALKYLLITHIUM COMPOUND, THEN REACTION WITH AN AMIDE OR ESTER AND TREATMENT WITH A CONCENTRATED ACID FOR CYCLIZATION | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
| CN-1162312-A | Phenyloxazolidinone antimicrobials | PHARMACIA & UPJOHN CO LLC (US) | 1997-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | NAMPT 998/4885CYP17A1 2708/4885RAB9A 1000/4885 |
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | NAMPT 972/4885CYP17A1 2609/4885RAB9A 897/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | NAMPT 2605/4885CYP17A1 2074/4885RAB9A 1146/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | NAMPT 998/4885CYP17A1 2708/4885RAB9A 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.